JAHA: Heart toxicity and cardiovascular biomarkers in breast cancer patients

Anti-cancer treatment in breast cancer patients is affected by the toxic reaction of the heart.
, such as the N-end of the prelude to B-sodium peptides (NT-proBNP) and hypersensitive myocardial tyromoprotein T, may have predictive value.
, researchers evaluated 853 patients with early breast cancer randomly grouped in the German breast cancer group GeparOcto-GBG 84 III using ultrasound heartbeats, electrocardiology, hemodynamic parameters, NT-proBNP, and hypersensitive cardiomyotrophin T.
patients were treated with a new auxiliary dose-enhanced table-soft star, yew alcohol, and cyclophosphamide (iddEPC group, n-424) or yew alcohol, non-polyethyl glycol atomycin and carbalin (yew alcohol, non-polyethyl glycol atomycin, carbaptonin group, n-429) for a total of 18 weeks.
patients who tested positive for human skin growth in 2 (n=354,41.5%) received monoclonal antibody therapy on the basis of distribution therapy.
119 patients (12.9%) of all patients had a cardiac toxicity reaction during treatment (using a stricter definition of 15 patients .
the occurrence of cardiac toxicity reactions was independent of the treatment group (P=0.31).
patients with cardiac toxicity reactions had a small but significant increase in early NT-proBNP compared to patients with heart NT-proBNP, which only increased at the end of treatment.
T was elevated in both groups of patients.
Logistic regression showed that the NT-proBNP (ratio of OR) measured in the first 6 weeks of treatment was 1.03; 95% CI was 1.008-1.055; P was 0.01) and hemoglobin (OR was 1.31; 95% CI was 1.05-1.63; P-0.02) was significantly associated with cardiac toxicity reactions.
results, NT-proBNP and hemoglobin were significantly associated with cardiac toxicity in patients with early stage breast cancer who received dose-enhanced chemotherapy, whereas hypersensitive heart ticklein T was not.